From: Dose escalation in advanced floor of the mouth cancer: a pilot study using a combination of IMRT and stereotactic boost
No. of patients (%)
EBRT regime
HART 72,5 Gy (1,45 Gy/fr. BID)
17 (46%)
HART 70 Gy (1,4 Gy/fr. BID)
14 (38%)
IMRT-SIB 70 Gy/56 Gy in 35fr. + cisplatin 40 mg/m2 weekly
6 (16%)
SRT boost
5 Gy in 1fraction
1 (3%)
10 Gy in 2fractions
36 (97%)